Figure 2 | Scientific Reports

Figure 2

From: Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C

Figure 2The alternative text for this image may have been generated using AI.

Changes in liver fibrosis stage based on LSM between SVR24 and SVR96 in HCV-infected patients treated with DAAs. LSM liver stiffness measurement, SVR sustained virological response, DAAs direct-acting antivirals. The grey area represents the regression of liver fibrosis after DAA therapy.

Back to article page